In a report released today, Salveen Richter from Goldman Sachs reiterated a Sell rating on Atara Biotherapeutics (ATRA – Research Report). The company’s shares closed yesterday at $1.21.
Richter covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, 2seventy bio, and Amgen. According to TipRanks, Richter has an average return of 20.5% and a 48.13% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Atara Biotherapeutics with a $6.55 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Atara Biotherapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.14 million and a GAAP net loss of $69.8 million. In comparison, last year the company earned a revenue of $4.46 million and had a GAAP net loss of $84.09 million
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics (ATRA) Company Description:
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Read More on ATRA:
- Atara Biotherapeutics files $400M mixed securities shelf
- Atara Biotherapeutics tab-cel deal worth $4-plus per share, says Mizuho
- Atara Biotherapeutics announces restructuring and 30% workforce reduction
- Atara expands global tab-cel partnership up to $640M with Pierre Fabre
- Atara Biotherapeutics reports Q3 EPS (66c), consensus (66c)
